Our first product is a cytokine inhibitor known as GLB333. This product once used can prevent the action of those molecules and mediators that are involved in the worsening of tissue injury and causing pain. GLB333 is a biopharmaceutical drug in the mid stage of development. The product is believed to have powerful effect on preventing the action of those cytokines that are release around the damaged tissue and lead to sever inflammation and pain. It is our belief this is only breakthrough in the management of systemic tissue injury and treatment of pain.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM